Landos Biopharma LABP

$ 22.93 0.58%

Annual report 2023
added 03-21-2024

Landos Biopharma Balance Sheet 2011-2024 | LABP

Annual Balance Sheet Landos Biopharma

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-	-	-2.42 M	-9.81 M	-359 K	-	-	-	-	-	-	-
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	73 M	-	-	-	-	-	-	-	-
Total Current Liabilities	6.25 M	6.12 M	16.6 M	-	-	-	-	-	-	-	-	-	-
Total Liabilities	6.25 M	6.12 M	16.6 M	11.3 M	76.1 M	1.8 M	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-155 M	-133 M	-94.2 M	-	-25.6 M	-9.14 M	-	-	-	-	-	-	-
Total Assets	38 M	45.3 M	92.9 M	30.3 M	50.5 M	2.8 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	37.5 M	36.6 M	8.3 M	2.42 M	-	-	-	-	-	-	-	-	-
Book Value	31.8 M	39.1 M	76.3 M	19 M	-25.6 M	1 M	-	-	-	-	-	-	-
Total Shareholders Equity	31.8 M	39.1 M	76.3 M	-54 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Landos Biopharma

	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	5.57 M	3.02 M	4.16 M	6.12 M	5.48 M	6.51 M	15.5 M	16.6 M	11.2 M	12.7 M	9.03 M	11.3 M	11.3 M	11.3 M	11.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-149 M	-143 M	-139 M	-133 M	-128 M	-120 M	-109 M	-94.2 M	-74.1 M	-61.4 M	-65.5 M	-55.7 M	-55.7 M	-55.7 M	-55.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	43.2 M	46.3 M	51.2 M	45.3 M	49.5 M	58 M	77.6 M	92.9 M	105 M	118 M	110 M	30.3 M	30.3 M	30.3 M	30.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	42.4 M	44 M	45.2 M	36.6 M	28.9 M	19.2 M	11.3 M	8.3 M	17.9 M	18.7 M	8.57 M	2.42 M	2.42 M	2.42 M	2.42 M	9.81 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	37.7 M	43.3 M	47 M	39.1 M	44 M	51.5 M	62.1 M	76.3 M	93.9 M	106 M	101 M	19 M	19 M	19 M	19 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	37.7 M	43.3 M	47 M	39.1 M	44 M	51.5 M	62.1 M	76.3 M	93.9 M	106 M	101 M	-54 M	-54 M	-54 M	-54 M	-25.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency